BIOPURE CORPORATION CASE PDF

It is early and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to. Biopure enters the field of blood substitutes: Human market – Hemopure; Veterinary market – Oxyglobin; Oxyglobin already received final FDA. Biopure Corp. case study. John T. Gourville. Save; Share. Save; Share. Format. PDF Hardcopy Black & White. Format. PDF, Hardcopy.

Author: Voodoonos Samurg
Country: Sudan
Language: English (Spanish)
Genre: Career
Published (Last): 11 August 2010
Pages: 157
PDF File Size: 7.18 Mb
ePub File Size: 13.24 Mb
ISBN: 407-6-17867-306-4
Downloads: 89131
Price: Free* [*Free Regsitration Required]
Uploader: Tojak

Exacerbating the problem is the nature of the biopharmaceutical industry, where product approval is never a certainty until achieved. It is very likely that the numbers will rise by the year of Oxyglobin release.

We noted that our pricing for Oxyglobin probably should be between the second question we have detailed presentation of this specific product pricing principles and price.

The raw material will cost 1. Biopure Corporation has two new products that are Oxyglobin and Hemopure. For new consumer package goods, for instance, one can look at past product rollouts, one can look at similar products currently in the marketplace, or one can do test markets—selling the product in a small section of the country to assess consumer acceptance.

In response to the timing of approval for these two products, there has been a long-running debate within Biopure as how to proceed with Oxyglobin. As for direct sales, it only takes 10 — 15 which is much cheaper. Business and Environment Business History Entrepreneurship.

Instead of making a contract with one of the distributors, Biopure should consider of distributing Oxyglobin by using its salesforces. Skip to main content. What is the market potential for Oxyglobin in the animal market and Hemopure in the human market? Remember me on this computer. Oxyglobin would generate the first revenues that Biopure could use to launch Hemopure. Ted Jacobs, vice president for Human Clinical Trials, is concerned about creating an unrealistic price expectation for Hemopure by marketing Oxyglobin before Hemopure.

  CUSCINETTI SKF CATALOGO PDF

So we think this is negative impact. Andy Wright and his team can have a successful launch for Oxyglobin by implementing the followings: Biopure Corporation Case 1. Quite often, for new products that represent incremental variations or improvements over existing products, marketers do a pretty good job of understanding how that product will be adopted in the marketplace.

Business case Biopure by Simone Huygens on Prezi

Case Summary Tetra Pak At odds are those in charge of Oxyglobin, who want to see the animal product released immediately, and those in charge of the Hemopure, who worry that an immediate release of Oxyglobin would create an unrealistically low price expectation for what they feel should be a very high-margin human product.

If the competitors want to get a share for animal blood substitutes, they have to wait at least for two years. Oxyglobin would create an unrealistic price expectation for Hemopure if released first.

Due to Rejection Due to Expiration Total: Finance Globalization Health Care. Gourville and David Arnold. It is early and Biopure Corp.

About the Author John T. Enter the email address you signed up with and we’ll email you a reset link. Strategic Marketing Management Name: If we set up a sales team with 50 staff, each staff will be responsible for 30 — 45 in one year. It would appear that, once the price is bound to make the hospitals, insurance companies, patients feel that this price is too high not to mention Oxyglobin the same company’s products.

And we cannot let the price difference to be unreasonably high since there is no essential difference between two products. Also, we noted blood transfusion is mainly used in emergency cases instead of ordinary cases. The motivation behind the push into digital was one of communicating and engaging with fans and potential fans around the world, as noted by Richard Lewis, Chief Executive of the AELTC.

A virtually identical product for the human market, Hemopure, is in the final stages of testing by Biopure and is expected to gain approval within one to two years. Instead, distributors work for many manufacturers and they will not be fully committed to Oxyglobin. All in all, as the corporatoin mover in this market, the Company should try their best to increase market penetration as soon as possible, even if selling the product at loss.

  FALK WRAPFLEX PDF

Predicting Diffusion John Gourville One job of product managers, marketers, strategic planners, and other corporate executives is to predict what the demand will be for a new product. I disagree with Ted Jacobs because although the production processes and physical ckrporation of these two products are identical, Oxyglobin is targeted biopurf the animal market whereas the target customer for Hemopure is the human market.

A strictly enforced ban on any player clothing other than white dated back to the s. If they release, what price should they set? What should Biopure do regarding the commercial release of Oxyglobin? Widely regarded as the most prestigious professional tennis tournament in the world and contested each year over two coporation in late June and early July, Wimbledon, in many ways, had changed little over the years. The coefficient is generally between 0. Cite View Details Educators Related.

So we can choose to price based on critical case.

Cite View Details Educators. I think that launching Oxyglobin has many benefits for the company. We noted that there is a big difference between critical case corpration noncritical case.

Biopure Corp.

However, some queries on the products we see they are indeed the existence of these links. He can only estimate these price points based corporstion the market price.

How might the presence of Oxyglobin be an asset or liability to Hemopure? We also have to cover the selling expenses.